<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633956</url>
  </required_header>
  <id_info>
    <org_study_id>747-209</org_study_id>
    <nct_id>NCT02633956</nct_id>
  </id_info>
  <brief_title>Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)</brief_title>
  <acronym>CONTROL</acronym>
  <official_title>A Phase 2, Randomized, Double Blind, Placebo Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects With Nonalcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercept Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an
      open-label long-term safety extension (LTSE), will evaluate the effect of Obeticholic Acid,
      and the subsequent addition of statin therapy, on lipoprotein metabolism in subjects with
      nonalcoholic steatohepatitis (NASH) with fibrosis stage 1 to 4, but no evidence of hepatic
      decompensation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2015</start_date>
  <completion_date type="Actual">March 12, 2018</completion_date>
  <primary_completion_date type="Actual">March 21, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effect of Obeticholic Acid on Low-density Lipoprotein (LDL) Concentration (Least Squares Mean Change From Baseline at Week 16)</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed nonalcoholic steatohepatitis (NASH) and the ability of atorvastatin to modulate this effect as measured by change (least squares mean) from baseline at week 16 in LDL concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effect of Obeticholic Acid on LDL Particle Size (Least Squares Mean Change From Baseline at Week 16)</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed NASH and the ability of atorvastatin to modulate this effect as measured by change from baseline (least squares mean) at week 16 in LDL particle size. It is LDL particle diameter size (nm) that is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Effect of Obeticholic Acid on LDL Particle Concentration (Total) (Least Squares Mean Change From Baseline at Week 16)</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed nonalcoholic NASH and the ability of atorvastatin to modulate this effect as measured by change (least squares mean) from baseline at week 16 in LDL particle concentration (total)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>5 mg Obeticholic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg Obeticholic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg Obeticholic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic Acid</intervention_name>
    <description>Once a day (QD) by mouth (PO)</description>
    <arm_group_label>10 mg Obeticholic Acid</arm_group_label>
    <arm_group_label>25 mg Obeticholic Acid</arm_group_label>
    <arm_group_label>5 mg Obeticholic Acid</arm_group_label>
    <other_name>OCA</other_name>
    <other_name>6alpha-ethylchenodeoxycholic acid (6-ECDCA)</other_name>
    <other_name>INT-747</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
    <arm_group_label>10 mg Obeticholic Acid</arm_group_label>
    <arm_group_label>25 mg Obeticholic Acid</arm_group_label>
    <arm_group_label>5 mg Obeticholic Acid</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once a day (QD) by mouth (PO)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. Histologic evidence of NASH, as assessed by central reading of a liver biopsy obtained
             no more than 1 year prior to randomization, defined by the presence of all 3 key
             histological features of NASH with a score of at least 1 for each and a combined score
             of 4 or greater out of a possible 8 points according to NASH Clinical Research Network
             (CRN) criteria.

          3. Histologic evidence of fibrosis stage 1 to stage 4 (as defined by NASH CRN scoring of
             fibrosis) without any evidence of hepatic decompensation.

          4. If subject has type 2 diabetes, is on stable dose of anti-diabetic medication (except
             thiazolidinediones [TZDs]) for ≥3 months prior to Day 1.

          5. Is either not taking or is on stable doses of TZDs and/or Vitamin E for ≥6 months
             prior to Day 1.

          6. Contraception: Female subjects of childbearing potential must use ≥1 effective method
             of contraception during the study and until 30 days following the last dose of
             investigational product. Effective methods of contraception are considered to be the
             following: barrier method, ie, condom (male or female) with spermicide or diaphragm
             with spermicide, intrauterine device, vasectomy (partner), hormonal (eg, contraceptive
             pill, patch, intramuscular implant or injection), abstinence (defined as refraining
             from heterosexual intercourse).

          7. Must provide written informed consent and agree to comply with the study protocol,
             including adherence to protocol-described statin withdrawal and statin therapy.

        Exclusion Criteria:

          1. Current or history of significant alcohol consumption for a period of more than 3
             consecutive months within 1 year prior to Screening Visit 1 (significant alcohol
             consumption is defined as more than 2 units/day in females and more than 4 units/day
             in males, on average)

          2. Prior intolerance to treatment with atorvastatin or other 3-hydroxy-3-methyl-glutaryl
             (HMG) Coenzyme A reductase inhibitors (including but not limited to rhabdomyolysis).

          3. LDL cholesterol ≥190 mg/dL and already on statin therapy at Screening Visit 1.

          4. LDL cholesterol &gt;200 mg/dL at any Screening Visit in subjects who are not on statin
             therapy, or at Screening Visit 2 in statin washout subjects.

          5. Planned change in diet or exercise habits during participation in the double-blind
             period, or a significant weight change of &gt;5% in the prior 6 months.

          6. Subjects who have undergone gastric bypass procedures (gastric lap band is acceptable)
             or ileal resection or plan to undergo either of these procedures.

          7. History of biliary diversion

          8. Uncontrolled diabetes defined as HbA1c ≥9.5% within 60 days prior to randomization
             (Day 1).

          9. Administration of any of the following medications as specified below:

               -  Prohibited 30 days prior to Day 1:

                    -  bile acid sequestrants (BAS) including cholestyramine and its derivatives,
                       colesevelam, colestipol, or

                    -  omega-3 fatty acid-containing dietary supplements

               -  Prohibited 3 months prior to Day 1:

                    -  nicotinic acid and derivatives, ezetimibe

                    -  any prescription or over-the-counter (OTC) medication or herbal remedy with
                       putative NASH efficacy (except Vitamin E or TZDs)

                    -  ursodeoxycholic acid

                    -  fenofibrate or other fibrates

                    -  any OTC or health food used to treat lipids including plant sterols and
                       berberine

               -  Prohibited 6 months prior to Day 1:

                    -  azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate,
                       mofetil, pentoxifylline; budesonide and other systemic corticosteroids, or

                    -  potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic
                       acid, isoniazide, or nitrofurantoin)

               -  Prohibited 12 months prior to Day 1:

                    -  antibodies or immunotherapy directed against interleukins, or

                    -  other cytokines or chemokines

         10. Evidence of other forms of chronic liver disease including but not limited to:

               -  Positive test result at Screening for hepatitis B surface antigen

               -  Active hepatitis C virus (HCV) infection (positive for HCV ribonucleic acid [RNA]
                  at Screening) or history of positive HCV RNA test result

               -  Primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis
                  or overlap syndrome

               -  Alcoholic liver disease

               -  Wilson's disease or hemochromatosis or iron overload

               -  Alpha-1-antitrypsin (A1AT) deficiency

               -  Prior known drug-induced liver injury within 5 years before Day 1

               -  Known or suspected hepatocellular carcinoma

         11. History of liver transplant, current placement on a liver transplant list, or current
             Model for End-Stage Liver Disease (MELD) score &gt;12. Subjects who are placed on a
             transplant list despite relatively early disease stage (eg, per regional guidelines)
             may be eligible as long as they do not meet any of the other exclusion criteria

         12. Presence of hepatic decompensation, including:

               -  Gastroesophageal varices

               -  Ascites

               -  Hepatic encephalopathy

               -  Spontaneous bacterial peritonitis

               -  Hepatorenal or hepatopulmonary syndromes

         13. Total bilirubin ≥2x upper limit of normal (ULN) at any Screening Visit (subjects with
             Gilbert's syndrome may be enrolled despite a total bilirubin level &gt;2x ULN if their
             conjugated bilirubin is &lt;2x ULN)

         14. Creatine phosphokinase &gt;5x ULN at Screening Visit 2

         15. Serum creatinine ≥1.5 mg/dL at any Screening Visit

         16. Serum alanine aminotransferase (ALT) &gt;300 U/L at any Screening Visit

         17. Platelet count &lt;75,000/mm3 at any Screening Visit

         18. Known positivity for human immunodeficiency virus (HIV) infection

         19. Subjects with recent history (within 1 year of randomization) of cardiovascular
             disease or with history or planned cardiovascular interventions to treat
             atherosclerotic cardiovascular disease

         20. Other concomitant disease, malignancy, or condition likely to significantly decrease
             life expectancy to &lt;5 years, including known cancers (except carcinomas in situ or
             other stable, relatively benign conditions such as chronic lymphocytic leukemia) and
             moderate to severe congestive heart failure.

         21. Known substance abuse, including inhaled or injected drugs in the year before
             Screening.

         22. For female subjects: pregnancy, planned or potential for pregnancy and unwillingness
             to use effective birth control during the study, or breastfeeding

         23. Participation in a clinical research study with any investigational product being
             evaluated for the treatment of diabetes or NASH in the 6 months before Day 1.

         24. Receipt of any investigational product not being evaluated for the treatment of
             diabetes or NASH from Screening Visit 1 to Day 1, within 30 days prior to Day 1, or
             within 5 half-lives of the compound before Day 1 (whichever was longer)

         25. Previous exposure to Obeticholic Acid

         26. History of known or suspected clinically significant hypersensitivity to Obeticholic
             Acid or any of its components

         27. Mental instability or incompetence, such that the validity of informed consent or
             ability to be compliant with the study is uncertain

         28. Any other condition which, in the opinion of the Investigator, would impede compliance
             or hinder completion of the study

         29. Acute cholecystitis or acute biliary obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Shapiro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Intercept Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miamai, Schiff Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Center of Gastroenterology</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic, P.A.</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen's Medical Center - Liver Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center, Institute for Digestive Health &amp; Liver Disease</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gastroenterology Liver Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute, LLC</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Associates of Texas, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <results_first_submitted>March 21, 2018</results_first_submitted>
  <results_first_submitted_qc>May 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2018</results_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-alcoholic Fatty Liver Disease</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Fatty Liver Disease</keyword>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02633956/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02633956/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects using statins within 30 days of the initial Screening visit (Screening Visit 1) are required to stop statin therapy immediately following this initial visit and must undergo a 4-week statin washout period prior to Screening Visit 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>5 mg Obeticholic Acid</title>
          <description>5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
        </group>
        <group group_id="P2">
          <title>10 mg Obeticholic Acid</title>
          <description>10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
        </group>
        <group group_id="P3">
          <title>25 mg Obeticholic Acid</title>
          <description>25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.
Placebo: Once a day (QD) by mouth (PO)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5 mg Obeticholic Acid</title>
          <description>5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
        </group>
        <group group_id="B2">
          <title>10 mg Obeticholic Acid</title>
          <description>10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
        </group>
        <group group_id="B3">
          <title>25 mg Obeticholic Acid</title>
          <description>25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.
Placebo: Once a day (QD) by mouth (PO)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="10.13"/>
                    <measurement group_id="B2" value="57.1" spread="11.62"/>
                    <measurement group_id="B3" value="62.2" spread="11.06"/>
                    <measurement group_id="B4" value="59.8" spread="9.88"/>
                    <measurement group_id="B5" value="58.1" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibrosis stage (NASH Clinical Research Network (CRN) categories)</title>
          <description>The NASH CRN Fibrosis Staging is based on the degree of liver fibrosis from Stage 0: no fibrosis to Stage 4: cirrhosis. The related histological classification of each stage is as follows: Fibrosis Stage: Stage 0: none; Stage 1a: zone 3 perisinusoidal, delicate; 1b: zone 3 perisinusoidal, dense; 1c: portal only; Stage 2: 1a or 1b + periportal fibrosis; Stage 3: bridging fibrosis; and Stage 4: cirrhosis.
The higher the fibrosis stage the worse the prognosis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stage 1 and 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage 3 and 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening LDL</title>
          <description>Fasting LDL concentration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less than or equal 125 mg/dL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Greater than 125 mg/dL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Effect of Obeticholic Acid on Low-density Lipoprotein (LDL) Concentration (Least Squares Mean Change From Baseline at Week 16)</title>
        <description>The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed nonalcoholic steatohepatitis (NASH) and the ability of atorvastatin to modulate this effect as measured by change (least squares mean) from baseline at week 16 in LDL concentration</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Efficacy evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Obeticholic Acid</title>
            <description>5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 Visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
          </group>
          <group group_id="O2">
            <title>10 mg Obeticholic Acid</title>
            <description>10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
          </group>
          <group group_id="O3">
            <title>25 mg Obeticholic Acid</title>
            <description>25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.
Placebo: Once a day (QD) by mouth (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Obeticholic Acid on Low-density Lipoprotein (LDL) Concentration (Least Squares Mean Change From Baseline at Week 16)</title>
          <description>The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed nonalcoholic steatohepatitis (NASH) and the ability of atorvastatin to modulate this effect as measured by change (least squares mean) from baseline at week 16 in LDL concentration</description>
          <population>Efficacy evaluable population</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.2" spread="4.93"/>
                    <measurement group_id="O2" value="-44.27" spread="4.10"/>
                    <measurement group_id="O3" value="-39.54" spread="4.24"/>
                    <measurement group_id="O4" value="-53.33" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimation</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>13.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.28</ci_lower_limit>
            <ci_upper_limit>25.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimation</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>9.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>20.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimation</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>20.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.33</ci_lower_limit>
            <ci_upper_limit>32.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Effect of Obeticholic Acid on LDL Particle Size (Least Squares Mean Change From Baseline at Week 16)</title>
        <description>The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed NASH and the ability of atorvastatin to modulate this effect as measured by change from baseline (least squares mean) at week 16 in LDL particle size. It is LDL particle diameter size (nm) that is reported.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Efficacy evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Obeticholic Acid</title>
            <description>5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
          </group>
          <group group_id="O2">
            <title>10 mg Obeticholic Acid</title>
            <description>10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 Visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
          </group>
          <group group_id="O3">
            <title>25 mg Obeticholic Acid</title>
            <description>25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 Visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.
Placebo: Once a day (QD) by mouth (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Obeticholic Acid on LDL Particle Size (Least Squares Mean Change From Baseline at Week 16)</title>
          <description>The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed NASH and the ability of atorvastatin to modulate this effect as measured by change from baseline (least squares mean) at week 16 in LDL particle size. It is LDL particle diameter size (nm) that is reported.</description>
          <population>Efficacy evaluable population</population>
          <units>nm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.15"/>
                    <measurement group_id="O2" value="-0.41" spread="0.12"/>
                    <measurement group_id="O3" value="-0.09" spread="0.12"/>
                    <measurement group_id="O4" value="-0.49" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimation</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimation</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimation</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Effect of Obeticholic Acid on LDL Particle Concentration (Total) (Least Squares Mean Change From Baseline at Week 16)</title>
        <description>The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed nonalcoholic NASH and the ability of atorvastatin to modulate this effect as measured by change (least squares mean) from baseline at week 16 in LDL particle concentration (total)</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>Efficacy evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Obeticholic Acid</title>
            <description>5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
          </group>
          <group group_id="O2">
            <title>10 mg Obeticholic Acid</title>
            <description>10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
          </group>
          <group group_id="O3">
            <title>25 mg Obeticholic Acid</title>
            <description>25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 Visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.
Placebo: Once a day (QD) by mouth (PO)</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Obeticholic Acid on LDL Particle Concentration (Total) (Least Squares Mean Change From Baseline at Week 16)</title>
          <description>The effect of Obeticholic Acid on LDL metabolism in subjects with biopsy confirmed nonalcoholic NASH and the ability of atorvastatin to modulate this effect as measured by change (least squares mean) from baseline at week 16 in LDL particle concentration (total)</description>
          <population>Efficacy evaluable population</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-224.79" spread="62.58"/>
                    <measurement group_id="O2" value="-325.04" spread="49.81"/>
                    <measurement group_id="O3" value="-336.22" spread="51.40"/>
                    <measurement group_id="O4" value="-439.84" spread="47.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimation</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>103.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>69.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.58</ci_lower_limit>
            <ci_upper_limit>242.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimation</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>114.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>68.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.53</ci_lower_limit>
            <ci_upper_limit>251.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Estimation</non_inferiority_desc>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>215.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>79.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.84</ci_lower_limit>
            <ci_upper_limit>374.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of first dose to end of double-blind phase participation, up to 16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>5 mg Obeticholic Acid</title>
          <description>5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
        </group>
        <group group_id="E2">
          <title>10 mg Obeticholic Acid</title>
          <description>10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
        </group>
        <group group_id="E3">
          <title>25 mg Obeticholic Acid</title>
          <description>25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Obeticholic Acid: Once a day (QD) by mouth (PO)
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
Atorvastatin: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.
Placebo: Once a day (QD) by mouth (PO)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="19" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators must wait 18 months after the study end to publish their results and a multi-center publication must come first. The sponsor has a 45 day review period with the option to extend to an additional 90 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Intercept Pharmaceuticals, Inc</organization>
      <phone>844-782-4278</phone>
      <email>medinfo@interceptpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

